Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases

NCT01939223 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01939223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01939223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Terminated
Start date
December 2, 2013
Completion date
August 29, 2016
Enrollment
25 (actual)
Sites
121

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms